FERRING
Ad hoc announcement pursuant to Art. 53 LR
Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million. This senior unsecured bond transaction is issued by Ferring Holding SA with 8-year maturity to 21st April 2031 at a fixed coupon rate of 3.25% per annum. The bonds will be listed on the SIX Swiss Exchange.
In a good market environment, the offering again attracted much interest from high-quality institutional investors and banks, demonstrating recognition of the company’s successful track record and the uplift in the credit rating. The company is rated by Credit Suisse as BBB with positive outlook and now similarly by Fedafin as Baa with stable outlook. This increase takes the second bond offering to CHF 240 million with 8-year maturity to 21st April 2031 at a fixed coupon rate of 3.25% per annum, plus CHF 250 million with 4-year maturity to 21st April 2027 at a fixed coupon rate of 2.70% per annum.
Dominic Moorhead, Chief Financial Officer of Ferring Pharmaceuticals, said: “Following the successful outcome of our second bond offering in March 2023 in a volatile market, we are pleased to be able to increase the amount by CHF 80 million in the longer tranche, in order to now total CHF 490 million balanced between 4-year and 8-year maturity. The uplift in our credit rating to dual mid-BBB is also good recognition of our progress in recent years. Following the approval of two ground-breaking products by the US Food and Drug Administration (FDA) in late 2022, we continue investing in the launch and manufacturing scale-up of these exciting growth opportunities.”
The net proceeds from the transaction will be used for general corporate purposes. The lead managers for the issue were Credit Suisse AG and Basler Kantonalbank.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.
Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230615332320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VeriSilicon Launches the Industry-Leading Automotive-Grade Intelligent Driving SoC Design Platform29.4.2025 02:00:00 CEST | Press release
Providing one-stop custom service from chip design and verification to automotive-grade certification VeriSilicon (688521.SH) recently announced that its automotive-grade high-performance intelligent driving system-on-chip (SoC) design platform has been verified and successfully implemented in customer projects. Leveraging VeriSilicon’s Silicon Platform as a Service (SiPaaS) business model, this platform provides robust technical support for high-performance computing applications such as autonomous driving and advanced driver assistance systems (ADAS). VeriSilicon’s chip design process has obtained ISO 26262 automotive functional safety management system certification, enabling the company to provide global customers with one-stop custom service for their automotive chips that meet functional safety requirements. Combined with its extensive portfolio of automotive-grade IPs and complete intelligent driving software platform, VeriSilicon offers end-to-end support from chip design and v
IFF Pharma Solutions to Showcase Portfolio at Excipient World 202528.4.2025 23:00:00 CEST | Press release
Sustainability Expert Will Share Key Insights on Industry-Leading Solutions for Improving Environmental Impact IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, will showcase its sustainable solutions at Excipient World 2025. The team will feature sustainable innovations, controlled-release formulations, and nitrosamine risk mitigation solutions at booth 205 from May 13-14, Gaylord National Resort and Convention Center, National Harbor, Maryland, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428283122/en/ “At IFF Pharma Solutions, we believe sustainability is not just a responsibility but an opportunity to innovate and inspire,” said Dr. Anne Adden, global strategic marketing director for sustainability and dietary supplements. “We are committed to creating solutions that not only meet the needs of today but also pave the way for a healthier, more sustainable future. Our team of problem-solve
Winka Dubbeldam Appointed Director and CEO of SCI-Arc28.4.2025 20:50:00 CEST | Press release
The Southern California Institute of Architecture (SCI-Arc) is thrilled to share that Prof. Winka Dubbeldam has been appointed as the next Director and Chief Executive Officer of SCI-Arc. A globally recognized Dutch architect, educator, and leader in design innovation, Winka will officially assume the role on September 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428994100/en/ Winka Dubbeldam Winka brings more than three decades of experience to the forefront of architectural practice and education. She is a full Professor of Architecture and served as Chair at the University of Pennsylvania Stuart Weitzman School of Design for ten years (2013–2023). Previously she initiated and directed the Post-Professional Architecture program for ten years (2003–2013), providing international students with innovative design skills, cutting-edge theoretical and technological knowledge necessary for a productive and innovativ
NIQ announces global data collaboration with The Trade Desk to enhance audience targeting28.4.2025 19:37:00 CEST | Press release
The Trade Desk is the first global technology platform to integrate new-to-market audiences NIQ, a leading consumer intelligence company, today announced a strategic global collaboration with The Trade Desk, a global leader in advertising technology. The collaboration will integrate NIQ's consumer intelligence and global insights on shopping behaviors into The Trade Desk’s platform, supporting marketers to plan and activate ad campaigns more accurately. These new-to-market audiences, now available on The Trade Desk's media buying platform, will enable advertisers to reach their desired audiences in global markets, with effectiveness and precision. "Our collaboration with The Trade Desk represents a significant step forward in our mission to provide actionable insights across the advertising industry, at a global scale," said Joshua Pisano, Global Head of Product, Media at NIQ. "By integrating NIQ’s advanced audiences into The Trade Desk’s leading data marketplace, we are empowering adv
Actus Nutrition Acquires Protein Facility from Foremost Farms USA28.4.2025 19:30:00 CEST | Press release
Deal includes exclusive long-term whey protein supply agreement Actus Nutrition (“Actus”), a leading vertically-integrated nutritional ingredients manufacturer and portfolio company of Butterfly Equity (“Butterfly”), today finalized an agreement to purchase a 99,000 sq. ft. processing facility from Foremost Farms USA (“Foremost Farms”). The facility, located in Sparta, WI, currently manufactures whey protein products, which Actus will continue producing at the location. As part of the deal, Actus and Foremost Farms will begin a long-term exclusive, network wide whey protein partnership supporting growth for both organizations. Actus plans to invest significant capital into the facility to increase capacity and expand its capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428226854/en/ Sparta, WI Facility “We’ll be able to hit the ground running because we can plug the Sparta facility into our existing manufactur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom